$3,006.80 consulting Payment -- Gilead Sciences to Dr. James Wilson
Gilead Sciences pays $3006.80 to Infectious Disease specialist for Biktarvy consulting
This page provides a detailed analysis of a $3,006.80 consulting payment from Gilead Sciences to Dr. James Wilson. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $3,006.80 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Gilead Sciences |
| Physician | Dr. James Wilson |
| NPI Number | 1191414905 |
| Physician Specialty | Infectious Disease |
| Location | Harrisburg, PA |
| Date of Payment | 2024-09-10 |
| Related Drug/Device | Biktarvy |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Gilead Sciences made a $3.0K consulting payment to James Wilson, a Infectious Disease specialist in Harrisburg, PA. The payment was associated with Biktarvy. The payment of $3006.80 to Dr. James Wilson for consulting services related to Biktarvy is a notable transaction. Gilead Sciences made this payment on September 10, 2024, indicating ongoing engagement with healthcare professionals. The payment falls under 'Consulting Fee' for 'Consulting' services, suggesting a specific advisory role.
Patient Guidance: What This Payment Means for You
This payment information is for transparency and does not imply endorsement of any specific drug or treatment. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for specialists in Infectious Disease can vary widely depending on the nature and duration of the consulting engagement.
Regulatory Context: Sunshine Act Requirements
This payment is reported under the Sunshine Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- consulting-fee
- gilead-sciences
- biktarvy
- infectious-disease
- healthcare-professional-payment
- cms-open-payments
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $3.0K payment for?
This was a consulting payment of $3.0K from Gilead Sciences to James Wilson, categorized as "Consulting Fee". It was associated with Biktarvy. The payment was reported under the Sunshine Act (CMS Open Payments).
Does James Wilson accept pharmaceutical money?
Yes, James Wilson received this $3.0K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view James Wilson's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $3.0K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Infectious Disease?
To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about James Wilson's relationship with Gilead Sciences?
The payment amount is specific, suggesting a defined scope of work for the consulting services. This $3.0K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Infectious Disease?
The payment is directly linked to a specific drug, Biktarvy, highlighting a focus on product-related engagement.
What should patients do after learning about this payment?
This payment information is for transparency and does not imply endorsement of any specific drug or treatment.
What else should I know about this consulting payment?
Dr. Wilson's specialty in Infectious Disease aligns with the typical use cases for Biktarvy.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.